Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Chairman Sells 8,500 Shares of Stock

Key Points

• Chairman Jurgi Camblong sold 8,500 SOPHiA GENETICS shares at an average price of $7.66, generating $65,110 under a pre-arranged Rule 10b5-1 plan. He still owns 3.44 million shares, and the sale reduced his stake by 0.25%.
• SOPH recently traded at $7.86, near its 12-month high of $8.98, with shares above both their 50-day and 200-day moving averages. However, the company remains unprofitable and missed quarterly EPS expectations despite exceeding revenue estimates.
• Analyst sentiment is mixed, with three Buy ratings, one Hold, and one Sell; the consensus rating is Hold with a $10 price target. Institutional ownership stands at 31.59%, with several funds initiating or expanding positions.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) Chairman Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $7.66, for a total value of $65,110.00. Following the completion of the sale, the chairman owned 3,435,822 shares in the company, valued at approximately $26,318,396.52. The trade was a 0.25% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jurgi Camblong also recently made the following trade(s):

• On Monday, August 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.61, for a total value of $64,685.00.
• On Friday, August 7th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.23, for a total value of $144,600.00.
• On Tuesday, August 4th, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.92, for a total value of $138,400.00.
• On Tuesday, July 21st, Jurgi Camblong sold 20,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $6.63, for a total value of $132,600.00.
• On Monday, July 20th, Jurgi Camblong sold 24,381 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.29, for a total value of $153,356.49.
• On Friday, July 10th, Jurgi Camblong sold 8,500 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.62, for a total value of $47,770.00.
• On Tuesday, July 7th, Jurgi Camblong sold 17,685 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.28, for a total transaction of $93,376.80.
• On Monday, July 6th, Jurgi Camblong sold 22,486 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.25, for a total transaction of $118,051.50.
• On Thursday, June 25th, Jurgi Camblong sold 1,373 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.70, for a total transaction of $7,826.10.
• On Friday, June 26th, Jurgi Camblong sold 50,069 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.80, for a total transaction of $290,400.20.

SOPHiA GENETICS Price Performance

SOPH traded down $0.01 on Monday, reaching $7.86. 309,330 shares of the company's stock were exchanged, compared to its average volume of 261,716. SOPHiA GENETICS SA has a twelve month low of $3.12 and a twelve month high of $8.98. The stock has a market cap of $659.38 million, a PE ratio of -6.83 and a beta of 0.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The stock's fifty day moving average price is $7.03 and its 200-day moving average price is $5.69.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.05). The business had revenue of $23.31 million during the quarter, compared to analysts' expectations of $21.72 million. SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. Sell-side analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current year.

Analysts Set New Price Targets

Several analysts have issued reports on SOPH shares. HC Wainwright upped their target price on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Weiss Ratings reissued a "sell (d-)" rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. BTIG Research upped their price objective on shares of SOPHiA GENETICS from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday, August 5th. Finally, Zacks Research upgraded shares of SOPHiA GENETICS to a "hold" rating in a report on Tuesday, July 21st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $10.00.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Maven Securities LTD acquired a new stake in SOPHiA GENETICS in the 2nd quarter valued at approximately $866,000. AXQ Capital LP acquired a new position in SOPHiA GENETICS during the second quarter worth $119,000. AWM Investment Company Inc. purchased a new position in shares of SOPHiA GENETICS during the second quarter worth $9,809,000. Hennion & Walsh Asset Management Inc. purchased a new position in shares of SOPHiA GENETICS during the second quarter worth $567,000. Finally, Royal Bank of Canada grew its stake in shares of SOPHiA GENETICS by 3,130.2% in the first quarter. Royal Bank of Canada now owns 19,381 shares of the company's stock valued at $96,000 after buying an additional 18,781 shares in the last quarter. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company's platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.